Bristol-Myers Squibb's (BMY) 'Disappointing' Opdivo Data in NSCLC has No Impact on Ratings - Moody's

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/14/2026

1. ADBE
2. SPCX
3. USO
4. SPY
5. RH
6. NVDA
7. RKLB
8. CRM
9. MSFT
10. DOL:CN

Go back to Bristol-Myers Squibb's (BMY) 'Disappointing' Opdivo Data in NSCLC has No Impact on Ratings - Moody's

Piper Jaffray Cuts Bristol-Myers (BMY) PT, Raises Merck's (MRK) Following BMY's CM-026 Failure

August 8, 2016 6:37 AM EDT

Piper Jaffray analyst Richard Purkiss lowered his price target on Neutral-rated Bristol-Myers Squibb Co. (NYSE: BMY) to $65.00 (from $69.00) following news Friday that its CheckMate-026 (CM-026) trial of Opdivo missed its primary endpoint in the treatment of PD-L1+ expressors (>5% PD-L1+,~55-60% of patients) in... More